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Protective eﬃ  cacy of prolonged co-trimoxazole prophylaxis 
in HIV-exposed children up to age 4 years for the prevention 
of malaria in Uganda: a randomised controlled open-label trial
Jaco Homsy, Grant Dorsey, Emmanuel Arinaitwe, Humphrey Wanzira, Abel Kakuru, Victor Bigira, Mary Muhindo, Moses R Kamya, 
Taylor G Sandison, Jordan W Tappero
Summary
Background WHO recommends daily co-trimoxazole for children born to HIV-infected mothers from 6 weeks of age 
until breastfeeding cessation and exclusion of HIV infection. We have previously reported on the eﬀ ectiveness of 
continuation of co-trimoxazole prophylaxis up to age 2 years in these children. We assessed the protective eﬃ  cacy and 
safety of prolonging co-trimoxazole prophylaxis until age 4 years in HIV-exposed children.
Methods We undertook an open-label randomised controlled trial alongside two observational cohorts in eastern 
Uganda, an area with high HIV prevalence, malaria transmission intensity, and antifolate resistance. We enrolled HIV-
exposed infants between 6 weeks and 9 months of age and prescribed them daily co-trimoxazole until breastfeeding 
cessation and HIV-status conﬁ rmation. At the end of breastfeeding, children who remained HIV-uninfected were 
randomly assigned (1:1) to discontinue co-trimoxazole or to continue taking it up to age 2 years. At age 2 years, children 
who continued co-trimoxazole prophylaxis were randomly assigned (1:1) to discontinue or continue prophylaxis from 
age 2 years to age 4 years. The primary outcome was incidence of malaria (deﬁ ned as the number of treatments for new 
episodes of malaria diagnosed with positive thick smear) at age 4 years. For additional comparisons, we observed 
48 HIV-infected children who took continuous co-trimoxazole prophylaxis and 100 HIV-unexposed uninfected children 
who never received prophylaxis. We measured grade 3 and 4 serious adverse events and hospital admissions. All 
children were followed up to age 5 years and all analyses were by intention to treat. This study is registered with 
ClinicalTrials.gov, number NCT00527800.
Findings 203 HIV-exposed infants were enrolled between Aug 10, 2007, and March 28, 2008. After breastfeeding ended, 
185 children were not infected with HIV and were randomly assigned to stop (n=87) or continue (n=98) co-trimoxazole 
up to age 2 years. At age 2 years, 91 HIV-exposed children who had remained on co-trimoxazole prophylaxis were 
randomly assigned to discontinue (n=46) or continue (n=45) co-trimoxazole from age 2 years to age 4 years. We 
recorded 243 malaria episodes (2·91 per person-years) in the 45 HIV-exposed children assigned to continue co-
trimoxazole until age 4 years compared with 503 episodes (5·60 per person-years) in the 46 children assigned to stop 
co-trimoxazole at age 2 years (incidence rate ratio 0·53, 95% CI 0·39–0·71; p<0·0001). There was no evidence of 
malaria incidence rebound in the year after discontinuation of co-trimoxazole in the HIV-exposed children who stopped 
co-trimoxazole at age 2 years, but incidence increased signiﬁ cantly in HIV-exposed children who stopped co-trimoxazole 
at age 4 years (odds ratio 1·78, 95% CI 1·19–2·66; p=0·005). Incidence of grade 3 or 4 serious adverse events, hospital 
admissions, or deaths did not signiﬁ cantly diﬀ er between HIV-exposed, HIV-unexposed, and HIV-infected children.
Interpretation Continuation of co-trimoxazole prophylaxis up to 4 years of age seems safe and eﬃ  cacious to protect 
HIV-exposed children living in malaria-endemic areas.
Funding Centers for Disease Control and Prevention Global AIDS Program, Doris Duke Charitable Foundation
Copyright © Homsy et al. Open Access article distributed under the terms of CC BY. 
Introduction
To reduce the risk of HIV-associated opportunistic 
infections, WHO recommends that infants born to HIV-
infected mothers and exposed to HIV through 
breastfeeding (HIV-exposed children) receive co-
trimoxazole prophylaxis from 6 weeks of age until 
breastfeeding ends and HIV infection can be excluded.1,2 
The rationale is that co-trimoxazole prophylaxis protects 
children who acquire HIV from their mothers against 
opportunistic infections including malaria and is 
inexpensive.3–8 However, this recommendation can be 
diﬃ  cult to implement because many HIV-exposed 
children are not retained in care beyond the last routine 
measles immunisation at 9–12 months of age, when 
breastfeeding might not have ended.9,10 Moreover, 
exclusion of HIV infection in infants younger than 
12 months has to be done via the detection of HIV DNA 
due to the persistence of maternal antibodies in HIV-
exposed children’s blood until 12–18 months of age,11,12 and 
HIV DNA testing can be costly and diﬃ  cult to access.13,14
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Every year, HIV and malaria combined cause 2·2 million 
deaths worldwide.15,16 In sub-Saharan Africa, more than 
1 million deaths every year are attributed to dual infection 
in children.16 In 2005, a randomised trial provided 
evidence that co-trimoxazole prophylaxis protected 
children aged 5–15 years against malaria in an area of 
Mali with low HIV prevalence.6 In 2011, we reported the 
results of a randomised controlled trial showing that 
prolongation of co-trimoxazole prophylaxis in HIV-
exposed children beyond breastfeeding cessation to age 
2 years was safe and resulted in a 39% protective eﬃ  cacy 
against malaria.17 We now present the ﬁ nal results of the 
trial up to age 5 years. Although incidence and mortality 
of severe Plasmodium falciparum malaria tend to peak in 
young children, especially in areas of high transmission 
intensity, the incidence of uncomplicated clinical malaria 
is relatively evenly distributed across the ﬁ rst 10 years of 
life in children in sub-Saharan Africa, independent of 
malaria transmission and seasonality patterns.18 Moreover, 
in areas of high transmission intensity such as our study 
setting of eastern Uganda, malaria incidence gradually 
increases until about 30 months of age and then gradually 
decreases, both in HIV-exposed and HIV-unexposed 
children.19 Our present hypotheses were that extending 
co-trimoxazole prophylaxis from age 2 to age 4 years 
would be associated with a reduction in the incidence of 
malaria and that between age 4 and age 5 years, the 
incidence of malaria would be higher among children 
who stopped co-trimoxazole at 4 years of age compared 
with children who stopped co-trimoxazole after cessation 
of breastfeeding or at 2 years of age. 
Methods
Study design and participants
We did a randomised controlled open-label trial with 
additional observational comparisons. Detailed setting 
characteristics and enrolment procedures have been 
described previously and are available online.17 Our study 
was done in Tororo, Uganda, where malaria is 
holoendemic, the entomological inoculation rate is 591 
infective bites per person-year,20 and the prevalence of 
antifolate resistance (dhfr/dhps quintuple mutant, 
composed of dhfr 51I, 59R, and 108N, and dhps 437G and 
540Q mutations) exceeds 90%.17,21,22 We used convenience 
sampling to enrol an interventional cohort of HIV-
exposed infants and two observational cohorts of HIV-
unexposed and HIV-infected infants from Tororo District 
Hospital and the AIDS Support Organization in Tororo, 
eastern Uganda. 
 Eligibility criteria for HIV-exposed infants were: babies 
born to an HIV-infected mother, age 6 weeks to 9 months,23 
HIV-negative status, currently breastfeeding, residing 
within 30 km of Tororo District Hospital, parental 
agreement to bring the child to Tororo District Hospital 
for any illness, avoidance of drugs outside the study 
protocol, absence of medical problems at screening, and 
parental provision of informed consent. Apart from HIV 
status, inclusion criteria were the same for HIV-infected 
and HIV-unexposed children, except that age of inclusion 
was from 6 weeks to 12 months for HIV-infected children. 
All participants were given an insecticide-treated bednet 
with instructions for use. We provided daily co-
trimoxazole prophylaxis drugs according to national 
guidelines.23,24 All mothers were counselled to exclusively 
breastfeed their infants until at least 6 months of age and 
then to wean according to national guidelines.23,25
The study protocol was approved by the Uganda 
National Council of Science and Technology and the 
institutional review boards of the University of California 
San Francisco, CA, USA; Makerere University, Kampala, 
Uganda; the University of Washington, Seattle, WA, USA; 
and the Centers for Disease Control and Prevention, 
Atlanta, GA, USA. We obtained written informed consent 
from parents or guardians. 
Randomisation and masking
Simple randomisation lists were computer generated by 
GD at the University of California, San Francisco, CA, 
USA. Sequentially numbered sealed envelopes containing 
the treatment group assignments were prepared from 
these lists, and allocated sequentially by a study nurse. 
Intervention assignments were not masked to 
investigators, parents, and assessors. 
Procedures
Before enrolment, we established mothers’ HIV status by 
rapid HIV testing (Determine Rapid Test for HIV-1, 
Abbott Laboratories, Abbott Park, IL, USA) and tested 
infants for HIV DNA by PCR assay (Amplicor HIV-1 
DNA PCR Test, version 1.5; Roche, Branchburg, NJ, USA) 
following Ugandan national HIV testing algorithms.26 We 
retested children 6–8 weeks after cessation of 
breastfeeding by HIV DNA PCR assay, and determined 
their ﬁ nal HIV status at age 18 months with rapid HIV 
testing and HIV DNA PCR. Positive PCR results were 
conﬁ rmed by repeat bleeding and quantitative HIV RNA 
PCR testing (Cobas Amplicor HIV-1 RNA Monitor Test, 
version 1.5; Roche).
We randomly assigned (1:1) HIV-exposed children who 
remained uninfected with HIV 6–8 weeks after 
breastfeeding cessation to discontinue co-trimoxazole 
immediately or to continue prophylaxis to age 2 years.17 At 
age 2 years, children previously assigned to continue 
prophylaxis were, for a second time, randomly assigned 
(1:1) to stop co-trimoxazole prophylaxis at age 2 years or to 
continue to age 4 years. At age 4 years, co-trimoxazole 
prophylaxis was stopped for all children. We followed up 
all children to age 5 years.
Participants attended a dedicated Tororo District 
Hospital clinic for all scheduled and unscheduled study 
visits. The clinic was open 7 days a week with after-hours 
care provided at the hospital. We monitored co-
trimoxazole adherence, bednet use, and children’s 
breastfeeding status and feeding practices through recall 
For the protocol see 
http://clinicaltrials.gov/ct2/
show/NCT00527800? 
term=NCT00527800&rank=1
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by parent or guardians at routine monthly visits.16 Infants 
assigned to continue prophylaxis were given a month-
long supply of co-trimoxazole at 30-day scheduled routine 
visits according to weight-based guidelines.16 We did a 
complete blood cell count every 90 days. Children who 
presented with tympanic temperature higher than 38°C 
or a history of fever in the previous 24 h were bled by 
ﬁ nger prick for laboratory assessment of thick smear. 
Thick smears were stained with 2% Giemsa stain for 
30 min and parasite density estimated.4 Children with a 
203 HIV-exposed breastfeeding uninfected children (aged 6 weeks to 9 months) given CTX prophylaxis
18 withdrawn 
6 moved out of study area
1 lost to follow-up
8 seroconverted to HIV
3 died
185 HIV-uninfected children aged 5–12 months old no longer breastfeeding 
98 randomly assigned to 
continue CTX prophylaxis 
until age 2 years*
87 randomly assigned to stop 
CTX prophylaxis at end of 
breastfeeding*
80 reached age 2 years91 reached age 2 years  
7 withdrawn 
3 moved out of 
study area
1 lost to follow-up
1 withdrew informed 
consent
2 died
7 withdrawn 
4 moved out of
study area 
1 seroconverted to HIV
1 unable to comply 
with protocol
1 died
45 assigned to continue CTX 
prophylaxis at age 2 years 
46 assigned to stop CTX
prophylaxis at age 2 years
9 withdrawn
5 moved out of 
study area
1 lost to follow-up
2 withdrew informed 
consent
1 unable to tolerate 
study drugs†
1 withdrawn 
1 unable to comply 
with protocol
45 reached age 4 years36 reached age 4 years and 
stopped CTX prophylaxis 
4 withdrawn 
3 moved out of 
study area
1 lost to follow-up
41 reached age 5 years36 reached age 5 years 
9 withdrawn
4 moved out of 
study area
2 lost to follow-up
2 withdrew informed 
consent
1 unable to comply 
with protocol
71 reached age 4 years 
2 withdrawn
1 lost to follow-up
1 died
69 reached age 5 years 21 reached age 5 years
21 reached age 4 years
19 withdrawn 
18 were enrolled in 
another study
1 died
40 reached age 2 years
8 withdrawn
4 moved out of 
study area
4 died
48 HIV-infected breastfeeding 
children (aged 6 weeks to 
12 months) given CTX 
prophylaxis
73 reached age 5 years
6 withdrawn
3 moved out of 
study area
2 lost to follow-up
1 withdrew informed 
consent
79 reached age 4 years
9 withdrawn
5 moved out of 
study area
1 lost to follow-up 
2 unable to comply 
with protocol
1 died
88 reached age 2 years
12 withdrawn
8 moved out of 
study area
1 withdrew informed 
consent
2 unable to comply 
with protocol
1 unable to tolerate 
study drugs
100 HIV-unexposed–
uninfected infants (aged 
6 weeks to 9 months) not 
given CTX prophylaxis
Figure 1: Study proﬁ le
CTX=co-trimoxazole. *Results of the ﬁ rst randomisation have been previously reported.17 †Unrelated to CTX: this child had recurrent episodes of hemolytic anaemia after treatment with 
dihydroartemisinin-piperaquine that were later shown to be due to glucose-6-phosphate dehydrogenase deﬁ ciency.
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positive thick smear were diagnosed with malaria, 
irrespective of parasite density. Haemoglobin 
measurements were made by spectrophotometry 
(HemoCue, Ängelholm, Sweden) on days 0 and 28 of a 
malaria episode. We deﬁ ned complicated malaria using 
standardised criteria.27
All children aged 4 months of age or older and weighing 
5 kg or more diagnosed with uncomplicated malaria 
received either open-label artemether-lumefantrine or 
dihydroartemisinin-piperaquine.28 Children with 
uncomplicated malaria younger than 4 months of age or 
weighing less than 5 kg and children diagnosed with 
complicated malaria were treated with standard doses of 
quinine. Children diagnosed with malaria returned on 
days 1, 2, 3, 7, 14, 21, 28, and on any day they were ill. 
Drugs with known antimalarial activity were avoided for 
the treatment of non-malarial infections. 
At monthly visits, study clinicians assessed children for 
adverse events and serious adverse events using the 
International Conference on Harmonization Guideline 
criteria.29 Children were withdrawn from the study if 
there was: a change of residence outside the study area, 
more than 60 days’ loss to follow-up, withdrawal of 
informed consent, poor adherence to study procedures, 
or inability to tolerate study drugs.
Outcomes
The primary outcome of this extension study was the 
incidence of malaria in HIV-exposed children who were 
allocated to co-trimoxazole at ﬁ rst randomisation and 
were subsequently allocated at second randomisation to 
stop or continue treatment until age 4 years. We also 
assessed incidence of malaria to 5 years in the two 
observational cohorts of HIV-unexposed children who did 
not receive any prophylaxis and HIV-infected children 
who received co-trimoxazole therapy until age 5 years. 
Our secondary endpoints were incidence of complicated 
malaria, diarrhoeal illnesses and respiratory tract 
infections, and rebound malaria in the year after stopping 
of co-trimoxazole prophylaxis. Our safety endpoints were 
numbers of adverse events, severe adverse events, 
hospital admissions, and death.
Statistical analysis
On the basis of ﬁ ndings from our previous trial of 
prolonging of co-trimoxazole prophylaxis to age 2 years 
(ﬁ rst randomisation),17 we assumed normally distributed 
data, 10% loss to follow-up, and two-sided α=0·05 with 
80% power to detect a 38% diﬀ erence in malaria incidence 
(3·04 vs 2·20 episodes per person-year) between two 
intervention groups of 100 HIV-exposed children each in 
our second randomisation. We deﬁ ned time-at-risk from 
day 1 post-randomisation until day of next randomisation 
or withdrawal from study, whichever came ﬁ rst. Malaria 
incidence was deﬁ ned as the number of new malaria 
episodes per person-time at risk and was reported in 
malaria episodes per person-year with associated 95% CIs. 
We compared malaria incidence and safety outcomes 
among all groups with negative binomial regression, 
adjusting for location of residence (urban vs rural, a 
characteristic previously associated with a lower incidence 
of malaria in urban areas30) and antimalarial treatment 
group. We deﬁ ned the protective eﬃ  cacy of a treatment 
with an incidence rate ratio (IRR) of the malaria incidence 
among children continuing co-trimoxazole divided by the 
incidence among those discontinuing co-trimoxazole. We 
used generalised estimating equations to measure 
associations between increasing age and daily risk of 
Study cohort, HIV-exposed children, second 
randomisation
Comparison cohorts
Daily CTX from age 
2–4 years (n=45)
Stopped daily CTX at 
age 2 years (n=46)
HIV-unexposed 
children not on CTX 
(n=88)
HIV-infected children on 
daily CTX since HIV 
diagnosis (n=48)
Girls 24 (53%) 18 (39%) 36 (41%) 25 (52%)
Median age at study enrolment (months) 3·0 (2·3–5·2) 3·3 (2·2–5·6) 5·4 (3·4–7·5) 5·6 (2·8–8·5)
Median age at breastfeeding cessation (months) 7·5 (6·0–10·6) 7·2 (6·4–8·9) 21·1 (18·3–23·2) 17·0 (9·6–20·8)
Median age at ﬁ rst randomisation (months) 10·1 (8·2–13·1) 9·6 (8·5–11·2) ·· ··
Time on co-trimoxazole before second randomisation or 
2 years of age (cumulative person-years)
74·8 75·9 0 72·8
Proportion using an insecticide-treated bednet* 97% 98% 98% 99%
Residing in Tororo town 12 (27%) 7 (15%) 18 (20%) 13 (27%)
Malaria incidence per person-year before second 
randomisation or 2 years of age
1·93† (1·63–2·27) 2·87†‡ (2·50–3·27) 4·68§ (4·32–5·05) 2·01 (1·69–2·37)
Data are n (%), median (IQR), or incidence (95% CI), unless otherwise indicated. CTX=co-trimoxazole. *Proportion of participants who reported sleeping under an ITN the 
previous night at the time of monthly routine clinic visits. †These incidence values are lower than those reported in our previous study17 or in table 2 because we used all 
observed person-time during follow-up to calculate time at risk to provide a better estimate of the number of treatments for malaria expected over time. In the previous 
study, we subtracted 14 days out of time at risk after each incident and treated episode of malaria. ‡p <0·06 for comparison with HIV-exposed children assigned to continue 
CTX until age 4 years. §p<0·0001 for comparison with either group of HIV-exposed children.
Table 1: Baseline characteristics of HIV-exposed children (age 2 years) and comparison cohorts at the time of the second randomisation
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malaria. A p<0·05 was considered statistically signiﬁ cant. 
We generated malaria incidence curves over age among 
children stratiﬁ ed by co-trimoxazole randomisation 
groups using Lowess smoothing with a bandwidth of 0·8. 
We double-entered data in Epi-Info and did statistical 
analysis with Stata version 10. All analyses were done on 
an intention-to-treat basis. This study is registered with 
ClinicalTrials.gov, number NCT00527800.
Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all 
the data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
Between Aug 10, 2007 and March 28, 2008, we enrolled 
203 HIV-exposed infants, 100 HIV-unexposed–uninfected 
infants, and 48 HIV-infected infants (ﬁ gure 1). 185 HIV-
exposed uninfected infants remained in the study at the 
time of the ﬁ rst randomisation; 98 were assigned to 
continue co-trimoxazole after breastfeeding ended, of 
these, seven (7%) withdrew before age 2 years, thus at 
second randomisation, we assigned 46 HIV-exposed 
children to stop co-trimoxazole and 45 HIV-exposed 
children to continue co-trimoxazole prophylaxis up to age 
4 years (ﬁ gure 1). Overall, 146 (79%) of 185 children in the 
primary analysis completed follow-up to age 5 years. In 
the observational cohorts, 21 of 48 (44%) HIV-infected 
children completed follow-up to age 5 years and 73 (73%) 
of the 100 HIV-unexposed and uninfected children 
remained in follow-up to age 5 years.
The groups of HIV-exposed children did not diﬀ er in 
age at enrolment, breastfeeding cessation, or ﬁ rst 
randomisation, or in adherence to co-trimoxazole before 
ﬁ rst randomisation (table 1). Across the interventional 
groups and the two observational cohorts, bednet use, 
treatment of uncomplicated malaria before second 
randomisation, or urban residence also did not 
signiﬁ cantly diﬀ er (table 1). Compared with HIV-exposed 
children, HIV-unexposed and HIV-infected children were 
enrolled at a slightly older age and were breastfed for 
longer as expected (table 1). Malaria incidence before the 
second randomisation was lower in HIV-exposed children 
assigned to continue co-trimoxazole from age 2 to 4 years 
than in those assigned to stop co-trimoxazole at age 
2 years, although this diﬀ erence did not reach statistical 
signiﬁ cance (IRR 1·48, 95% CI 0·98–2·22; p=0·06).
The 91 HIV-exposed children assigned to discontinue or 
continue co-trimoxazole prophylaxis from age 
2 years to 4 years had 746 malaria episodes. Of these, 
243 (2·91 per person-years) episodes occurred among the 
45 children randomly assigned to continue co-trimoxazole 
until age 4 years, whereas 503 episodes (5·60 per person-
years) occurred in the 46 children randomly assigned to 
stop co-trimoxazole at age 2 years (table 2). Thus at age 
4 years, the 45 HIV-exposed children who continued co-
trimoxazole had a 47% lower risk of malaria than had the 
46 children who stopped co-trimoxazole at age 2 years 
(IRR 0·53, 95% CI 0·39–0·71, p<0·0001). Similarly, the 
non-randomised comparison between the 45 HIV-
exposed children who continued co-trimoxazole from age 
2–4 years and the 80 children who stopped taking co-
trimoxazole at breastfeeding cessation indicated an IRR 
of 0·53 (95% CI 0·43–0·67; p<0·0001; table 2).
By age 4 years, the 40 HIV-infected children on 
continuous daily co-trimoxazole prophylaxis had 166 
malaria episodes (2·66 per person-years)—a 53% lower 
risk of malaria than the 80 HIV-exposed children who 
stopped taking co-trimoxazole at breastfeeding cessation 
(IRR 0·47, 95% CI 0·37–0·60; p<0·0001; table 2), and a 
51% lower risk of malaria than had the 88 HIV-unexposed 
children who never received prophylaxis (0·49, 0·38–0·61; 
p<0·0001).
n CTX prophylaxis status Episodes Person-
years
Incidence 
PPY
IRR 
(95% CI)*
p value
Enrolment (end of BF)
HIV-exposed 203 On CTX since age 6 weeks 142 105·5 1·35 ·· ··
Before age 2 years†
HIV-exposed 87 CTX stopped after end of BF 400 86·9 4·60 Ref ··
HIV-exposed 98 On CTX until age 2 years 305 104·1 2·93 0·66
(0·52–0·82)
0·0003
HIV-
unexposed‡
100 Not on CTX 674 145·7 4·63 ·· ··
HIV-
infected‡
48 On CTX since age 6 weeks 142 73·5 1·93 ·· ··
Between age 2 years and 4 years
HIV-exposed 80 CTX stopped after end of 
BF
900 151·2 5·95 Ref ··
HIV-exposed 46 CTX stopped at age 2 years 503 89·9 5·60 0·96
(0·78–1·17)
0·69
HIV-exposed 45 On CTX until age 4 years 243 83·4 2·91 0·53
(0·43–0·67)
<0·0001
HIV-
unexposed‡
88 Never on CTX 959 164·8 5·82 0·99
(0·84–1·17)
0·91
HIV-
infected‡
40 On CTX since HIV diagnosis 166 62·4 2·66 0·47
(0·37–0·60)
<0·0001
Between age 4 years and 5 years
HIV-exposed 71 CTX stopped after end of 
BF
371 69·7 5·32 Ref ··
HIV-exposed 36 CTX stopped at age 2 years 204 42·4 4·81 0·93
(0·73–1·18)
0·54
HIV-exposed 45 CTX stopped at age 4 years 167 36·2 4·61 0·92
(0·71–1·20)
0·55
HIV-
unexposed‡
79 Never on CTX 383 76·8 4·99 0·97
(0·79–1·18)
0·74
HIV-
infected‡
21 On CTX since HIV diagnosis 59 22·8 2·59 0·55
(0·42–0·69)
<0·0009
PPY=per person-year of follow-up. IRR= incidence rate ratio. CTX=co-trimoxazole. BF=breastfeeding. *Malaria IRR 
(95% CI), controlling for place of residence and antimalarial treatment group. †For randomised groups, incidence is 
from cessation of breastfeeding to 2 years of age. For observational cohorts is from enrolment (6 weeks to 12 months 
of age) to 2 years of age. ‡Observational cohorts, not randomised.
Table 2: Incidence of any malaria among groups according to co-trimoxazole randomisations and ages
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Overall, from ﬁ rst randomisation after breastfeeding 
cessation to age 4 years, 133 children not prescribed co-
trimoxazole had 5·50 (95% CI 5·25–5·76) malaria 
episodes per person-years, whereas 98 children prescribed 
co-trimoxazole had 2·92 (2·68–3·18) malaria episodes 
per person-years, representing a protective eﬃ  cacy of 
43% (IRR 0·57, 95% CI 0·47–0·69, p<0·0001). Thus, daily 
co-trimoxazole prophylaxis prevented an average of 
2·63 episodes of malaria per year per HIV-exposed child 
between the ages of 2 years and 4 years.
To assess whether the protective eﬃ  cacy of co-
trimoxazole changed over time and whether dis-
continuation of co-trimoxazole prophylaxis was followed 
by a rebound incidence of malaria, we plotted malaria 
incidence after the ﬁ rst and second randomisations in 
relation to age (ﬁ gure 2). Moreover, to complement 
table 2 and ﬁ gure 2, we looked at associations between 
malaria incidence and age between ages 30 months 
and 60 months (table 3). There were no signiﬁ cant 
diﬀ erences in malaria incidence in the year after 
randomisation between children who stopped co-
trimoxazole prophylaxis after breastfeeding (odds ratio 
[OR] 0·84; 95% CI 0·78–0·90), at age 2 years (OR 0·86; 
95% CI 0·79–0·93) and at age 4 years (OR 0·86; 95% CI 
0·78–0·94; table 3). The diﬀ erence in malaria incidence 
between HIV-exposed children randomised after 
breastfeeding cessation or at age 2 years was constant 
with increasing age, as was the diﬀ erence in incidence 
between HIV-unexposed children and HIV-infected 
children, and between these groups and the randomised 
HIV-exposed children (ﬁ gure 2).
Malaria incidence in HIV-unexposed children who 
never received prophylaxis was similar to that in 
HIV-exposed children who discontinued co-trimoxazole 
at breastfeeding cessation, whereas malaria incidence 
among HIV-infected children who remained on co-
trimoxazole until age 5 years was similar to that of HIV-
exposed children who continued co-trimoxazole 
prophylaxis to age 4 years (table 2, ﬁ gure 2). Malaria 
incidence between 48 months and 60 months of age was 
stable or decreased for HIV-exposed children who 
discontinued co-trimoxazole at breastfeeding cessation or 
age 2 years, whereas it rose rapidly for children who 
discontinued co-trimoxazole at age 4 years (OR 1·78, 
95% CI 1·19–2·66; p=0·005; ﬁ gure 2). In keeping with 
these patterns, table 3 shows a signiﬁ cant and consistent 
association between increasing age and decreasing risk of 
malaria from 30–60 months of age for HIV-unexposed 
children and HIV-exposed children who stopped co-
trimoxazole after breastfeeding cessation or age 2 years. 
By contrast, increasing age was associated with increased 
risk of uncomplicated malaria between 48–60 months of 
age in HIV-exposed children who stopped prophylaxis at 
age 48 months, whereas there was no signiﬁ cant 
association between age and risk of any malaria among 
HIV-infected children aged 30–60 months taking co-
trimoxazole prophylaxis (table 3). None of the children 
who were on extended co-trimoxazole prophylaxis until 
2 or 4 years of age had complicated malaria during follow-
up from age 4 years to 5 years.
Few episodes of complicated malaria occurred. In the 
two intervention groups and two observational cohorts, 
only 59 of 5618 (1%) treated malaria episodes were 
complicated (appendix). Of these, 45 occurred in children 
not prescribed co-trimoxazole (incidence 5·2 per 
100 person-years) compared with 14 episodes among 
children on co-trimoxazole (incidence 3·1 per 100 person-
years) showing a 55% protective eﬃ  cacy of co-trimoxazole 
against complicated malaria (IRR 0·45; p<0·0001). 
We recorded 116 hospital admissions for all causes 
among all groups of children during the 5 years of follow-
up, 83 (72%) of which occurred in HIV-exposed children. 
Age range OR* (95% CI) p value
HIV-unexposed: never on 
CTX
30–60 months 0·84
(0·78–0·90)
<0·0001
HIV-exposed: CTX stopped 
after breastfeeding
30–60 months 0·86
(0·79–0·93)
<0·0001
HIV-exposed: CTX stopped 
at age 24 months
30–60 months 0·86
(0·78–0·94)
<0·0001
HIV-infected: always on 
CTX
30–60 months 1·08
(0·83–1·39)
0·57
HIV-exposed: CTX stopped 
at age 48 months
48–60 months 1·78
(1·19–2·66)
0·005
OR=odds ratio. CTX=co-trimoxazole. *Daily odds of being diagnosed with malaria 
per 12 month increase in age within the indicated range using generalised 
estimating equations to measure the associations between increasing age and the 
daily risk of malaria for the diﬀ erent CTX exposure groups. 
Table 3: Daily risk of malaria with increasing age in relation to HIV status 
and exposure to co-trimoxazole prophylaxis
Figure 2: Malaria incidence in relation to age for all groups
CTX=co-trimoxazole. BF=breastfeeding. Full lines represent time when children were on CTX. Dotted lines represent 
time when children were not on CTX. The ﬁ rst randomisation of HIV-exposed children occurred at the end of 
breastfeeding, between 6 weeks and 9 months of age. The second randomisation of HIV-exposed children 
occurred at age 24 months.
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See Online for appendix
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The rate of admissions did not signiﬁ cantly diﬀ er between 
any group at any point during follow-up (appendix). 
Overall, 43 admissions occurred among HIV-exposed 
children on co-trimoxazole from enrolment to age 4 years, 
compared with 38 admissions in HIV-exposed children 
not on co-trimoxazole during the same period. We found 
no signiﬁ cant diﬀ erences in the incidence of pneumonia 
or diarrhoea between the randomised prophylaxis groups 
at any age (appendix).
HIV-exposed children who remained on co-trimoxazole 
up to age 4 years had a 49% lower risk of grade 3 and 
4 serious adverse events compared with HIV-exposed 
children who discontinued co-trimoxazole at age 2 years. 
This diﬀ erence could be attributed to the signiﬁ cant 
diﬀ erence in incidence of raised temperature at the time 
of malaria diagnosis (table 4). There was no signiﬁ cant 
diﬀ erence between the groups of HIV-exposed children in 
either median haemoglobin levels at day 0 of each malaria 
episode, or mean changes in haemoglobin between day 0 
and day 28 of malaria follow-up (data not shown). The 
incidence of neutropenia and thrombocytopenia from 
scheduled quarterly complete blood cell counts was not 
signiﬁ cantly diﬀ erent between groups (table 4). Lastly, 
13 children died in total: two HIV-exposed children not on 
co-trimoxazole; ﬁ ve HIV-exposed children on co-
trimoxazole; ﬁ ve HIV-infected children on co-trimoxazole; 
and one HIV-unexposed child never on co-trimoxazole 
(ﬁ gure 1). No deaths were attributed to co-trimoxazole 
administration.
Discussion
This is the ﬁ rst randomised trial assessing the protective 
safety and eﬃ  cacy of prolonged daily co-trimoxazole 
prophylaxis against malaria in HIV-exposed children to 
age 4 years (panel). Continuation of co-trimoxazole 
prophylaxis beyond the period of HIV exposure (end of 
breastfeeding) until age 4 years was safe and provided an 
overall protective eﬃ  cacy against malaria of 43% in an 
area characterised by very high malaria transmission 
intensity and antifolate plasmodium resistance.17 
Moreover, compared with children not receiving 
prophylaxis, children receiving prophylaxis had a 55% 
lower risk of complicated malaria, a major cause of death 
in children younger than 5 years.
We noted no evidence of malaria incidence rebound in 
the year after co-trimoxazole prophylaxis when stopped 
after breastfeeding cessation or at age 2 years. Indeed, 
after children reached 30 months of age there was an 
inverse association between age and risk of malaria in 
HIV-unexposed children, and in HIV-exposed children 
who stopped co-trimoxazole after breastfeeding cessation 
or at age 2 years. These ﬁ ndings are probably due to the 
development of naturally acquired antimalarial immunity 
in these children,35–37 and are consistent with ﬁ ndings 
from a 2009 pooled analysis of six randomised controlled 
trials, and two more recent trials on intermittent 
preventive therapy in infancy in Mozambique and 
Discontinued 
CTX prophylaxis 
at age 2 years
Continued CTX 
prophylaxis 
from age 
2–4 years
IRR (95% CI) p value
All grade 3–4 adverse events 215 (1·216) 111 (0·592) 0·51 (0·36–0·72) <0·0001
Individual grade 3–4 adverse events*
Raised temperature 133 (0·752) 48 (0·256) 0·35 (0·24–0·51) <0·0001
Anaemia 67 (0·379) 51 (0·272) 0·69 (0·34–1·40) 0·31
Neutropenia 10 (0·057) 9 (0·048) 0·85 (0·34–2·15) 0·73
Thrombocytopenia 5 (0·028) 2 (0·011) 0·36 (0·06–2·33) 0·28
All serious adverse events 33 (0·187) 31 (0·165) 0·91 (0·42–1·98) 0·81
All data given as n (incidence per person-years at risk). There were 177 person-years at risk in the discontinued CTX 
group and 188 person-years at risk in the continued CTX group. CTX=co-trimoxazole. *Only includes children with at 
least ﬁ ve total events. †Raised temperature deﬁ ned as tympanic temperature higher than 38°C.
Table 4: Safety outcomes in HIV-exposed children randomly assigned to discontinue or continue CTX 
prophylaxis to age 4 years
Panel: Research in context
Systematic review
We searched PubMed, Medline, the National Library of Medicine, and CAB Abstracts for 
papers or abstracts published between 2000 and 2014, in English and French, with the 
keywords: “co-trimoxazole”, “malaria”, “HIV”, “children”, “infants”, “Africa”, “prophylaxis”, 
and “randomized”. Although there have been no randomised controlled trials for the 
protective eﬃ  cacy of co-trimoxazole prophylaxis against malaria in HIV-exposed uninfected 
infants apart from the ﬁ rst publication from this study,17 co-trimoxazole prophylaxis has 
shown many beneﬁ ts in HIV-infected and HIV-uninfected children in sub-Saharan Africa. In 
2004, Chintu and colleagues8 reported a 43% reduction in mortality in HIV-infected 
Zambian children aged 1–14 years randomly assigned to co-trimoxazole prophylaxis 
compared with placebo without increased adverse events and despite high levels of 
common bacterial resistance to co-trimoxazole. Shortly thereafter, Mermin and colleagues31 
showed that mortality for HIV-negative Ugandan family members living with an HIV-
infected person decreased by 63% and these family members had a reduced incidence of 
malaria after the HIV-infected person started daily co-trimoxazole prophylaxis. In a setting 
of low antifolate resistance, Thera and colleagues6 reported that co-trimoxazole prophylaxis 
among Senegalese children aged 5–15 years had a 99·5% protective eﬃ  cacy against clinical 
malaria compared with no prophylaxis, and that co-trimoxazole did not induce antifolate 
resistance in plasmodia infecting these children. However, these children were followed up 
for 3 months and were not tested for HIV.6 Kamya and colleagues4 showed that co-
trimoxazole prophylaxis in combination with bednets had a 97% protective eﬃ  cacy against 
malaria in HIV-infected children aged 1–11 years in Kampala, Uganda. Moreover, several 
African observational studies have reported that HIV-exposed uninfected infants had 
signiﬁ cantly higher morbidity and mortality risks than did infants born to HIV-uninfected 
mothers, and that this risk increased with advanced HIV disease in the HIV infected 
mothers, prompting strong calls for child survival interventions, including co-trimoxazole 
prophylaxis for all HIV-exposed children.32–34 None of these studies, nor a trial to assess the 
safety and eﬃ  cacy of nevirapine prophylaxis in combination with co-trimoxazole 
prophylaxis until breastfeeding cessation in HIV-exposed children,3 reported evidence of 
adverse events associated with co-trimoxazole prophylaxis.
Interpretation
Our randomised comparison of HIV-exposed children allocated to receive diﬀ erent 
durations of co-trimoxazole prophylaxis reliably reinforce existing evidence that 
continuing co-trimoxazole prophylaxis in HIV-exposed children beyond the period 
recommended by WHO up to age 4 years was safe and eﬃ  cacious to prevent malaria.
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Kenya.37–39 In these studies, no substantial rebound eﬀ ect 
occurred after intermittent preventive therapy in the 
second year of life of the children who received it. 
However, none of these trials followed up children beyond 
age 2 years or studied continuous daily prophylaxis. Our 
observation that malaria incidence increased signiﬁ cantly 
from age 4 years to 5 years in children who stopped co-
trimoxazole at 4 years of age raises the possibility that 
extension of co-trimoxazole prophylaxis to age 4 years 
might have delayed the development of natural immunity. 
The curves in ﬁ gure 2 all show an inﬂ exion point around 
36 months of age, suggesting that this might be the time 
of acquisition of natural immunity. However, the fact that 
neither the incidence of complicated malaria nor that of 
adverse events (data not shown) increased in the year 
after stopping of co-trimoxazole prophylaxis at any age 
suggests that the beneﬁ ts of preventing of nearly half of 
all malaria infections earlier in life outweighs the risks 
associated with rebound. Why co-trimoxazole can have 
such a marked eﬀ ect on malaria incidence in an area of 
high endemicity and high grade of multiple antifolate 
resistance to sulfadoxine–pyrimethamine is not entirely 
clear. Possible explanations include the fact that daily 
dosing of co-trimoxazole might achieve higher blood 
concentrations and longer periods of protection than does 
intermittent preventive therapy with sulfadoxine–
pyrimethamine, and that resistant parasites do not have 
identical resistance proﬁ les to co-trimoxazole and 
sulfadoxine–pyrimethamine.40–42
This trial had several limitations: although HIV-
exposed treatment groups were randomly assigned, the 
HIV-infected and HIV-unexposed children were not 
randomised and thus were not directly comparable to 
HIV-exposed children. The self-reported nature of co-
trimoxazole adherence, bednet use, and infant feeding 
practice might have been aﬀ ected by respondent bias. At 
the time of the second randomisation, the baseline 
incidence of malaria was lower in HIV-exposed children 
randomised to continue co-trimoxazole from age 2 years 
to age 4 compared to those randomised to stop co-
trimoxazole at age 2 years (table 1). Although this 
diﬀ erence occurred by chance, it might have resulted in a 
slight overestimation of the protective eﬃ  cacy of co-
trimoxazole in HIV-exposed children between age 2 years 
and age 4 years. There were also insuﬃ  cient complicated 
malaria episodes to allow for meaningful statistical 
comparisons of this outcome across the HIV-exposed 
intervention groups and the two observational cohorts. 
Safety outcomes were not systematically collected for the 
observational cohorts or for HIV-exposed children after 
discontinuation of co-trimoxazole prophylaxis at age 
4 years. Thus, safety outcomes could not be compared 
across the HIV-exposed intervention groups and the two 
observational cohorts. Although the trial was not 
designed to assess the eﬃ  cacy of co-trimoxazole against 
bacterial infections or the development of resistance to 
bacterial pathogens potentially attributable to co-
trimoxazole, we noted no signiﬁ cant diﬀ erences in the 
incidence of pneumonia or diarrhoea between the 
randomised prophylaxis groups at any age (appendix) 
and ample evidence exists to show that the eﬃ  cacy of 
continuous co-trimoxazole prophylaxis in HIV-infected 
children is neither aﬀ ected by, nor increases, pathogens’ 
resistance to the drug.6,8,43 Lastly, we did not follow up 
children beyond age 5 years, thereby limiting our ability 
to assess further the eﬀ ect of stopping prophylaxis on 
malaria incidence and rebound in older children.
The 2013 Consolidated WHO Guidelines for Treating 
and Preventing HIV Infection recommend to start 
lifelong triple antiretroviral drug therapy (ART) in HIV-
infected pregnant women, irrespective of WHO clinical 
stage or CD4 cell count.2 When it achieves virological 
suppression, ART started in pregnancy can reduce the 
risk of antenatal and intrapartum HIV transmission 
from infected mother to infant by more than 98%,44 and 
is expected to cause a similar reduction in the cumulative 
risk of mother-to-child HIV transmission through 
breastfeeding. As these guidelines are widely 
implemented, the number of children infected by their 
mother will greatly decrease, and the number of HIV-
exposed uninfected children will increase accordingly. 
Given the lack of evidence regarding the protective 
eﬃ  cacy of co-trimoxazole prophylaxis against diarrhoea 
and respiratory infections in HIV-exposed uninfected 
children, the beneﬁ ts of the standing recommendation 
for these children have been questioned and the 
potential risks of toxicity and resistance raised.45,46 Our 
previous and present ﬁ ndings, as well as the studies 
reviewed, clearly establish the substantial protection co-
trimoxazole prophylaxis confers against malaria for all 
children, irrespective of HIV status and antifolate 
resistance levels.47,48 As malaria continues to exert high 
mortality on all children younger than 5 years 
worldwide,15,16,19,30,49 this combined evidence provides a 
rationale for safe and eﬃ  cacious continued co-
trimoxazole prophylaxis against malaria in HIV-exposed 
children up to at least 2 years of age and possibly to 4 
years if the beneﬁ ts of malaria prevention between ages 
of 2 years and 4 years outweigh the risk of malaria 
incidence rebound after 4 years of age. This could prove 
to be a simple and highly cost-eﬀ ective measure to 
reduce drastically the public health burden and social 
impact of malaria in these children and their families in 
areas where malaria is endemic. An important 
implementation question would be whether to continue 
recommending daily co-trimoxazole or a better 
antimalarial for prophylaxis given the possibility of 
emergence of additional high-level antifolate resistance-
mediating mutations that might follow the widespread 
use of co-trimoxazole prophylaxis.21 In the high malaria 
transmission intensity setting of this study, intermittent 
preventive therapy with artemisinin-based combination 
therapy in infants has been shown to provide 58% 
protective eﬃ  cacy as compared with no chemoprevention 
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in HIV-unexposed infants aged 6 months to 2 years.48 It 
remains to be seen whether similar combinations are 
equally safe and eﬀ ective for children up to 5 years old. 
In any event, innovative means to ensure practical 
implementation and monitoring of malaria chemo-
prophylaxis, whether extended to age 2 years or beyond, 
and of other health, nutritional, and environmental 
interventions50 that play an important role in malaria 
prevention, are critically needed to close the wide gap that 
currently exists between the millions of HIV-exposed and 
infected children who need co-trimoxazole prophylaxis 
worldwide and the less than 10% of those who are 
presently taking it.1,51
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